Catestatin as a potential diagnostic marker of metabolic syndrome
https://doi.org/10.31146/1682-8658-ecg-235-3-148-151
Abstract
Aim of the study: to evaluate the possibility of using catestatin as a biomarker for the diagnosis of metabolic syndrome. Materials and methods: the study was based on a search for publications mainly over the past 5 years in the PubMed and Google Scholar databases for the keywords “catestatin”, “metabolic syndrome”, “insulin resistance”, “dyslipidemia”. Results: catestatin is a multifunctional peptide that can become a promising tool for the diagnosis of metabolic syndrome. It affects the adrenergic system, reducing sensitivity to catecholamines and causing vasodilation. In addition, catestatin affects the metabolism, reducing the levels of triglycerides and leptin. It also regulates insulin resistance and has an anti-inflammatory effect. Conclusion: catestatin may be a useful tool for the diagnosis and treatment of metabolic syndrome. However, further research is needed to fully understand its role and determine best practices.
About the Authors
D. K. Kuznetsova
Samara State Medical University
Russian Federation
Russian Federation
I. V. Gubareva
Samara State Medical University
Russian Federation
Russian Federation
A. V. Pashentseva
Samara State Medical University
Russian Federation
Russian Federation
References
1. Bourebaba Y., Mularczyk M., Marycz K., Bourebaba L. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome. Biomed Pharmacother. 2021 Feb;134:111113. doi: 10.1016/j.biopha.2020.111113.
2. Zalewska E., Kmieć P., Sworczak K. Role of Catestatin in the Cardiovascular System and Metabolic Disorders. Front Cardiovasc Med. 2022;9:909480. Published 2022 May 19. doi: 10.3389/fcvm.2022.909480.
3. Watanabe T. The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease.Int J Mol Sci. 2021 Jun 6;22(11):6118. doi: 10.3390/ijms22116118.
4. Meng L., Ye X.J., Ding W.H. et al. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown). 2011;12(9):643-647. doi: 10.2459/JCM.0b013e328346c142.
5. O’Connor D.T., Zhu G., Rao F. et al. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation. 2008 Jul 15;118(3):247-57. doi: 10.1161/CIRCULATIONAHA.107.709105.
6. Gubareva E. Yu., Kryukov N.N., Gubareva I.V. catestatin as a novel marker of cardiovascular risk in systemic hypertension.Russian Journal of Cardiology. 2018;(4):111-116. (In Russ.) doi: 10.15829/1560-4071-2018-4-111-116.@@ Губарева Е.Ю., Крюков Н.Н., Губарева И.В. катестатин как новый маркер сердечно-сосудистого риска у больных гипертонической болезнью. Российский кардиологический журнал. 2018;(4):111-116. doi: 10.15829/1560-4071-2018-4-111-116.
7. Durakoğlugil M.E., Ayaz T., Kocaman S.A. et al. The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. Anatol J Cardiol. 2015 Jul;15(7):577-85. doi: 10.5152/akd.2014.5536.
8. Mahata S.K., Corti A. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci. 2019;1455(1):34-58. doi: 10.1111/nyas.14249.
9. Ying W., Mahata S., Bandyopadhyay G.K. et al. Catestatin Inhibits Obesity-Induced Macrophage Infiltration and Inflammation in the Liver and Suppresses Hepatic Glucose Production, Leading to Improved Insulin Sensitivity. Diabetes. 2018 May;67(5):841-848. doi: 10.2337/db17-0788.
10. Dasgupta A., Bandyopadhyay G.K., Ray I. et al. Catestatin improves insulin sensitivity by attenuating endoplasmic reticulum stress: In vivo and in silico validation.Comput Struct Biotechnol J. 2020 Feb 22;18:464-481. doi: 10.1016/j.csbj.2020.02.005.
11. Muntjewerff E.M., Christoffersson G., Mahata S.K., van den Bogaart G. Putative regulation of macrophage-mediated inflammation by catestatin. Trends Immunol. 2022 Jan;43(1):41-50. doi: 10.1016/j.it.2021.11.002.
Review
For citations:
Kuznetsova D.K., Gubareva I.V., Pashentseva A.V. Catestatin as a potential diagnostic marker of metabolic syndrome. Experimental and Clinical Gastroenterology. 2025;(3):148-151. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-235-3-148-151
Views:
1
Email this article 